SCHEMBL2029802

SCHEMBL2029802

CNC(=O)c1ccccc1Nc1nc(Nc2ccc(P(C)(C)=O)cc2)ncc1C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 16/20 0.65
▸ CDC7 O00311 1/20 0.63
▸ ROCK2 O75116 1/20 0.63
▸ MAP4K4 O95819 1/20 0.63
▸ PIM1 P11309 1/20 0.63
▸ PRKACA P17612 1/20 0.63
▸ CDK7 P50613 1/20 0.63
▸ CDK9 P50750 1/20 0.63
▸ HIPK2 Q9H2X6 1/20 0.63
▸ IRAK4 Q9NWZ3 1/20 0.63
▸ KDR P35968 2/20 0.62
▸ JAK2 O60674 1/20 0.62
▸ NTRK1 P04629 1/20 0.62
▸ TYK2 P29597 1/20 0.62
▸ JAK3 P52333 1/20 0.62
▸ PTK2B Q14289 1/20 0.62
▸ NTRK3 Q16288 1/20 0.62
▸ NTRK2 Q16620 1/20 0.62
▸ AURKB Q96GD4 1/20 0.55
▸ MAPK9 P45984 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12586455 0.92 CDC7 (0.60) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL25692495 0.89 PTK2 (0.68) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL31260481 0.88 PTK2 (0.67) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL2051845 0.88 PTK2 (0.62) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL2637056 0.88 PTK2 (0.66) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL31653644 0.86 PTK2 (0.65) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL26123046 0.86 PTK2 (0.65) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL2637548 0.86 PTK2 (0.62) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL2636840 0.86 PTK2 (0.64) PTK2CDC7ROCK2MAP4K4PIM1
SCHEMBL25241734 0.86 PTK2 (0.67) PTK2CDC7ROCK2MAP4K4PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438056-B1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS LLC (US) 2017-12-20 — — EP claimed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US claimed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US claimed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US claimed
EP-2438056-B1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS LLC (US) 2017-12-20 — — EP disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS PTK2 2/4885CDC7 1045/4885ROCK2 1990/4885
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS PTK2 2/4885CDC7 1045/4885ROCK2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback